Cargando…

Targeted Interference with Signal Transduction Events

Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Groner, B. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2007.
Edición:1st ed. 2007.
Colección:Recent Results in Cancer Research, 172
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-3-540-31209-3
003 DE-He213
005 20230810201414.0
007 cr nn 008mamaa
008 100301s2007 gw | s |||| 0|eng d
020 |a 9783540312093  |9 978-3-540-31209-3 
024 7 |a 10.1007/978-3-540-31209-3  |2 doi 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 571.978  |2 23 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Targeted Interference with Signal Transduction Events  |h [electronic resource] /  |c edited by B. Groner. 
250 |a 1st ed. 2007. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg :  |b Imprint: Springer,  |c 2007. 
300 |a IX, 188 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Recent Results in Cancer Research,  |x 2197-6767 ;  |v 172 
505 0 |a Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy -- Identifying Critical Signaling Molecules for the Treatment of Cancer -- Tyrosine Kinase Inhibitors and Cancer Therapy -- Targeting ERBB Receptors in Cancer -- Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches -- Inhibition of the TGF-? Signaling Pathway in Tumor Cells -- The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition -- The Ras Signalling Pathway as a Target in Cancer Therapy -- The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment -- Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events. 
520 |a Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book. 
650 0 |a Cancer. 
650 0 |a Oncology. 
650 0 |a Medicine  |x Research. 
650 0 |a Biology  |x Research. 
650 1 4 |a Cancer Biology. 
650 2 4 |a Oncology. 
650 2 4 |a Biomedical Research. 
700 1 |a Groner, B.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783642068348 
776 0 8 |i Printed edition:  |z 9783540819547 
776 0 8 |i Printed edition:  |z 9783540312086 
830 0 |a Recent Results in Cancer Research,  |x 2197-6767 ;  |v 172 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-3-540-31209-3  |z Texto Completo 
912 |a ZDB-2-SME 
912 |a ZDB-2-SXM 
950 |a Medicine (SpringerNature-11650) 
950 |a Medicine (R0) (SpringerNature-43714)